RareResearch.AI
← Back to atlas

E140K

Category 4 — Stable Fold, Function DisruptedUncertain significanceCytoplasmic · predictedSource card
Glutamic acidLysine at position 140 · N-terminal cytoplasmic (intrinsically disordered) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type E140 — ionic bond to K143
Fullscreen ↗
DynaMut2 mutant · E140K
Mutant K140 — ionic bond to K143 lost (3 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

3 lost1 gained7 preserved
Interaction typeWild-type partnerMutant partnerStatus
Ionic bondK143Lost
Hydrogen bondK143K143Preserved
Hydrogen bondL144L144Preserved
Polar contactR138R138Preserved
Polar contactV142Lost
Polar contactK143K143Preserved
Polar contactL144L144Preserved
Van der WaalsV142Lost
Van der WaalsL144L144Preserved
HydrophobicT104T104Preserved
HydrophobicR138Gained

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.57kcal/mol
Destabilising — mild
AlphaMissense
0.444
ambiguous
AlphaFold pLDDT
91
model confidence
Schema
Cat 4
Category 4 — Stable Fold, Function Disrupted
ΔΔG confidence: Standard confidence · Cytoplasmic

This variant is in a water-facing region, which is the regime the stability predictor was built and benchmarked for. Ordinary predictor error still applies.

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditions
Population frequency (gnomAD v4)Ultra-rare · AF 0.0016%
cDNA changec.418G>A
ClinVar accessionVCV001299985
Last evaluated2024/10/07 00:00

Observed at very low frequency in gnomAD.

Classified for2★ documented assertion

ClinVar classifies this variant as Uncertain significance, but does not state what it is classified for. ClinVar records no condition for this variant. A classification without a phenotype and an inheritance mode cannot be read as a statement about Wolfram syndrome risk or severity.

  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 2★ multiple submitters, no conflicts. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.0016% · 26 / 1,585,526 alleles
Homozygotes
0
Highest-frequency population
Remaining individuals · AF 0.0033%

Highest in Remaining individuals: AF 0.0033% (2 of 61,478 alleles), in line with the global figure.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
Middle Eastern · under-sampled0.017%1 / 6,0500
Remaining individuals0.0033%2 / 61,4780~1 in 15370
Admixed American · under-sampled0.0018%1 / 55,6300
European (non-Finnish)0.0017%20 / 1,166,5420~1 in 29160
African / African American · under-sampled0.0013%1 / 74,4320
South Asian · under-sampled0.0012%1 / 86,7160

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Full Variant Card

WFS1 Wolframin — E140K Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Glutamic acid → Lysine at position 140. N-terminal cytoplasmic (intrinsically disordered). ClinVar Uncertain significance, AlphaMissense 0.444, DynaMut2 ΔΔG -0.57 kcal/mol (destabilising).


Identity

FieldValue
VariantE140K (p.Glutamic acid140Lysine)
DNA changec.418G>A
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV001299985
Amino acid changeGlutamic acid (E) → Lysine (K)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 14091.25 — well-folded
DomainN-terminal cytoplasmic (intrinsically disordered)
Position contextN-terminal cytoplasmic (intrinsically disordered)
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 140 sits in N-terminal cytoplasmic (intrinsically disordered). The wild-type residue is negatively charged (glutamate — carboxylate); the mutant is positively charged (lysine — primary amine). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.4443
am_classambiguous
InterpretationLikely benign (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-0.57 (Destabilising)
Job ID178094715044
Result URLJob 178094715044 · retrieved 2026-06-08 — result self-hosted by RareResearch.AI (Biosig no longer serves this page)

Clinical Evidence

Inheritance and scope

Uncertain significance — phenotype scope not stated in ClinVar

ClinVar classifies this variant as Uncertain significance, but does not state what it is classified for. ClinVar records no condition for this variant. A classification without a phenotype and an inheritance mode cannot be read as a statement about Wolfram syndrome risk or severity.

Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient. Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Last evaluated2024/10/07 00:00
InheritanceInheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscapeE140K is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

(no conditions catalogued)


Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 4 — Stable Fold, Function Disrupted

<strong>Category 4 — Stable Fold, Function Disrupted</strong><br/><br/>|ΔΔG|=0.57 negligible. Likely site-specific functional disruption — docking strategy.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.57 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.444. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • E140K_molstar_viewer.html — interactive 3D viewer (auto-highlights position 140 with ball-and-stick + neighbors within 5Å)
  • E140K_variant_card.md — this card (source of truth)
  • E140K_variant_card.html — styled printable card
  • E140K_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • E140K_wildtype_interactions.pse / E140K_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the E140K PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download E140K PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.